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Li-Fraumeni Syndrome (LFS) is an autosomal dominant genetic disorder associated with mutations in the
TP53 gene and characterized by a propensity to develop a variety of malignancies resulting in a shortened
lifespan. We report a case of prostate cancer in a 50 year old male with LFS. Experimental studies suggest
that TP53 mutations in prostate cancer are associated with therapeutic resistance to radiation, chemo-
therapy, and anti-androgens, implying that LFS men may experience more aggressive cancer biology with
implications for therapeutic decisions. The potential of prostate cancer to develop earlier in LFS favors
institution of screening at earlier ages.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Li-Fraumeni Syndrome (LFS) is a cancer predisposition syn-
drome with dominant inheritance in which affected individuals
display TP53 gene mutations and diverse tumor types.1 The spe-
ciﬁc type of TP53 gene mutation, combined with unique envi-
ronmental and lifestyle exposures, may account for the
heterogenous patterns of cancer at different ages. Familial TP53
mutations may be as high as 1:5000.1 As recognition of LFS im-
proves and cancer screening/surveillance strategies for impacted
individuals are instituted, many malignancies will be detected
earlier with higher rates of cure and enhanced longevity.2 Thus,
those caring for urologic cancers are likely to observe a rise in the
number of LFS-Prostate Cancer (PCa) patients secondary to longer
life expectancies. If PCa risk is indeed increased by LFS, a diagnosis
at a younger age with more aggressive biology may be predicted.
We report a case of clinically localized PCa in a 50-year-old LFS
male and discuss implications for clinical assessment, ongoing
surveillance, and medical management.Atwell Hall, Columbus, OH
210.
Inc. This is an open access article uCase presentation
A 50-year-old male presented for primary care evaluation and
underwent his ﬁrst PCa screening with a normal DRE and PSA of
4.41 ng/mL. The family history was signiﬁcant for PCa in a paternal
uncle (72y) and cousin (60y). His family history was also signiﬁcant
for LFS, having been genotyped at age 49. The limited family
pedigree shows the individuals, their cancer diagnoses, age, sur-
vival status, and genetic test results if known (Fig. 1). Our case was
free of other cancers except for a solitary 4 cm skin lesion consistent
with limited stage mycosis fungoides (T-cell lymphoma) treated
with topical steroids and in remission (Fig. 2).
Transrectal biopsy revealed two of eight cores with adenocar-
cinoma, one on the left lateral base, Gleason grade 3 þ 4 ¼ 7
involving 40% of the specimen, and the left base with a 3 þ 3 ¼ 6
carcinoma involving 1% of the sample. After considering options,
he proceeded with an uncomplicated radical robotic-assisted
prostatectomy and lymph node resection. Pathologic staging
showed adenocarcinoma, Gleason 3 þ 3 ¼ 6, involving 5% of the
gland, multifocal, bilateral cancer apex to base, within a back-
ground of diffuse high grade prostatic intraepithelial neoplasia
without nodal involvement or extracapsular extension and a
staging of pT2cN0Mx.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Partial Li-Fraumeni Syndrome (LFS) case pedigree. Offspring of LFS positive individuals included in pedigree; LFS negative offspring excluded. Age of death noted within
geometric shape. Diagnosed cancers listed under shapes: 1 ¼ prostate; 2 ¼ brain; 3 ¼ breast; 4 ¼ lymphosarcoma; 5 ¼ melanoma; 6 ¼ lymphoma; 7 ¼ renal.
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Caregivers involved in management of genitourinary cancers
should examine family history for evidence of multiple and early-
onset cancers. The prompt recognition of heredity cancer syn-
dromes, such as LFS, may have important management and
prognostic value includingmore effective screening for at-risk family
members. Adrenocortical cancer andWilm’s tumor/nephroblastoma
are two urological malignancies established as core cancers of LFS
(others include: sarcoma, osteosarcoma, pre-menopausal breast
cancer, brain cancer, and leukemia), and their detection should
trigger a careful evaluation of the family history.1,3
Improved awareness and identiﬁcation of LFS is providing an
opportunity for aggressive cancer screening and tailored surveil-
lance in LFS families. This approach is allowing LFS patients toFigure 2. Estimated cancer-free survival curves and prostate cancer incidence by age.
Cancer-free survival plotted for non-LFS carriers against male LFS carriers. Prostate
cancer incidence for all races and African Americans.successfully treat cancers at curable stages, achieve greater
longevity, and men are surviving to ages over 40 where PCa rates
dramatically increase over 100-fold during the subsequent three
decades.4 At present, data is insufﬁcient to deﬁne prostate cancer as
an LFS core cancer, particularly with sporadic prostate cancer being
the most common visceral cancer among men in Western nations.4
The high prevalence of genetic defects in p53 signaling pathways
based upon genomic analysis of human prostate cancer5 suggests a
potential for prostate cancer to be one of the LFS core malignancies.
Future monitoring of LFS families through a national/international
database will address this issue.4
Decisions regarding the age at which to begin prostate cancer
screening andhow frequently to repeat suchassessmentswill need to
be incorporated into a comprehensive cancer LFS surveillance pro-
gram, which continues to evolve. Although public health guidelines
for PCa screening remain controversial,we strongly favor treating LFS
men as high-risk and empirically initiating the screening programno
later than age 40 until data accumulates to guide our efforts more
precisely. Obviously, in an asymptomatic male whose life expectancy
is less than 5 years (if an active lethal cancer or comorbidities are
present), the more urgent health issues may supersede the impor-
tance of screening and detection of an early PCa.
Surgical interventions for cancer have been successfully employed
with curative and palliative intent in LFS without evidence of unex-
pected complications. Thus, otherwise healthy men with substantial
life expectancies are candidates for a radical prostatectomy with
curative intent.6Wedonot favor ionizing radiation (IR) therapy, either
external beam or brachytherapy, for treatment for clinically localized
prostate cancer in LFS, as p53 dysfunction is associated with relative
radio-resistance in cancer.7More critically,mutant p53 contributes to
defective DNA repair, and LFS patients experience greater risk of
developing secondary cancers due to radiation-induced oncogenic
transformation.1 The risk to individuals with LFS of developing a
second primary cancer is 57%, and the risk of a third is approximately
38%.1 Limiting exposure to radiation therapy and judicious utilization
of diagnostic radiology is recommended.1
Chemotherapy is employed in neoadjuvant and adjuvant clinical
trials for those with locally advanced prostate cancer with a high
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Unfortunately, many therapeutic agents can induce DNA damage,
increasing the risk of future malignancy.8 Not surprisingly, p53
protein mutations also confer drug resistance in multiple cancers.9
Reported chemoresistance in dysfunctional p53 cancers include
docetaxel, doxorubicin, cisplatin, anthracyclines, and mitoxan-
trone.9,10 Thus far, the efﬁcacy of taxane-based chemotherapeutics
in LFS are largely unknown.10
Conclusion
LFS is an inherited cancer syndrome with urologic cancers
(adrenocortical cancer and nephroblastoma) as core malignancies.
The improved screening, detection, and treatment of cancers in LFS
families is allowing LFS men to live longer lives and survive into the
decades where prostate cancer is more prevalent. It is prudent to
consider men with LFS as high risk and institute screening at ages
earlier than for the general population. Surgical intervention for
localized disease, as opposed to radiotherapy and systemic
chemotherapy or hormonal therapy, is preferable when cure is
possible. The optimal management of LFS patients is early detection
of prostate cancer at a stage where curative surgical interventions
are likely to be successful and the subsequent need for chemo-
therapy and radiotherapy will be low.
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